14th CROI (Conference on Retroviruses and Opportunistic Infections) Los Angeles, California Feb 25-28, 2007

Conference Reports for NATAP


15th CROI Conference on Retroviruses and Opportunistic Infections Boston, MA Feb 3-6, 2008

	HIV and the Brain, Neuropathogenesis HIV and the Brain: Report from the 15th Conference on Retroviruses and Opportunistic Infections. - Written by Scott Letendre, J. Allen McCutchan, and Ronald J. Ellis - (03/10/08) New ARTs Recently Approved & Key ART Clinical Studies Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08) Endothelial Activation Markers Are Linked to HIV Status and Are Independent of ART and Lipoatrophy - (03/05/08) New and emerging antiretrovirals, Comparative ART Trials, and when to begin HAART after an OI- now or later - written by David Margolis, MD (02/25/08) CROI: CCR5 Antagonists, Tropism Assays: Entry and Entry Inhibitors at 15th Conference on Retroviruses and Opportunistic Infections 2008 -Written by Eric S. Daar, M.D. (02/14/08) 48-Week Raltegravir Data Confirm Salvage Potency Across Pretreatment Variables - Written by Mark Mascolini - (02/27/08) 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08) 48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08) Efficacy and Safety of Double-Boosted Saquinavir (SQV)/Lopinavir/Ritonavir (LPV/r) in Nucleoside Pretreated Children at 96 Weeks - (02/26/08) Abacavir/3TC vs TDF/FTC: The HEAT Study - Written by Mark Mascolini (02/05/08) Kaletra Tablets Once vs Twice Daily - Written by Mark Mascolini (02/14/08) Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naive (ARV) HIV-1 Infected Subjects (02/06/08) Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/12/08) Boosted Atazanavir Noninferior to Lopinavir in Previously Untreated People - Written by Mark Mascolini (02/05/08) Efficacy and Safety of Boosted Once-Daily Atazanavir and Twice-Daily Lopinavir Regimens in Treatment-Naive HIV-1 Infected Subjects CASTLE: 48-Week Results (02/05/08) This is a BMS press release CASTLE STUDY SHOWED SIMILAR EFFICACY BETWEEN ONCE-DAILY REYATAZ (atazanavir sulfate)/RITONAVIR AND TWICE-DAILY LOPINAVIR/RITONAVIR AT 48 WEEKS IN PREVIOUSLY UNTREATED HIV-INFECTED ADULT PATIENTS (02/07/08) Etravirine With Darunavir Stays Strong Through 48 Weeks in DUET Trials - Written by Mark Mascolini (02/14/08) Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates (02/07/08) DUET-1:Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients (02/07/08) Pharmacokinetics and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2 (02/07/08) New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy (02/07/08) Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive (02/07/08) Characterization of virologic failures on darunavir/ritonavir in the randomized, controlled, Phase III TITAN trial in treatment-experienced patients (02/07/08) Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (02/07/08) Once-Daily Darunavir Troughs Stay in Active Range for All ARTEMIS Patients - Written by Mark Mascolini (02/12/08) Failure and Resistance Differences Between Darunavir and Lopinavir in TITAN - Written by Mark Mascolini - (02/26/08) Darunavir EvaLuation in Pediatric HIV-1-Infected treatment-experienced patients, DELPHI (Trial TMC114-C212) - (02/26/08) Do Lipid Signals Favor Maraviroc Over Efavirenz in Untreated People? - Written by Mark - (02/26/08) Fasted Lipid Changes after Administration of Maraviroc or Efavirenz in Combination with Zidovudine and Lamivudine (Combivir) for 48 Weeks to Treatment-naive HIV-infected Patients (02/05/08) Multistudy Analysis Shows Enhanced CD4 Gain With CCR5 Antagonists - Written by Mark Mascolini (02/12/08) Maraviroc 48-Weeks Safety, Efficacy in Treatment-Experienced MOTIVATE 1 and 2 Study Pooled Analysis (02/12/08) Tropism Change from Screening to Baseline Matters: Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-Naive Patients (02/06/08) What Explains Maraviroc Failures in the MERIT Trial of Naive Patients? - Written by Mark Mascolini (02/05/08) An Enhanced Version of the Trofile HIV Co-receptor Tropsim Assay Predicts Emergence of CXCR4 Use in ACTG5211 Vicriviroc Trial Samples - (02/19/08) Detection of Viral Co-receptor Tropism Changes with a High Sensitivity Phenotypic Assay among HIV-infected Patients with Drug-resistant Viremia - (02/19/08) Co-Morbidities Women, Younger Age & Black Race Associated with Shorter Time to Viral Failure: Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection - (03/21/08) Risk for Cardiovascular Disease and Regional Adipose Tissue Depots Among HIV-infected Men and Women in the Study of Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) (03/12/08) Inflammatory Markers Correlate with Carotid Intima-Media Thickness and Endothelial Activation in HIV-infected Patients (03/12/08) MELD is the Best Predictor of Pre-transplant Mortality in HIV-infected Liver Transplant Candidates???? NO - (03/07/08) Prevalence and Risk Factors in HIV-infected Persons for Echocardiographic Abnormalities in the Era of Modern HAART - (03/05/08) Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis - (03/07/08) Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (03/07/08) Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08) Diastolic Dysfunction is Common in Asymptomatic HIV Patients - (03/07/08) Cardiovascular Risk Markers Greatly Inflate Death Risk in People With HIV; interruptions increase risk - Written by Mark Mascolini (02/12/08) Lower Noninfectious Disease Rates With HAART in All CD4 Brackets - Written by Mark Mascolini (02/19/08) Fat Changes Boost Heart Disease and Diabetes Risk in HIV-Infected Men - Written by Mark Mascolini (02/19/08) Resuming Therapy Can't Reverse Progression Risk With Off-and-On Therapy - Written by Mark Mascolini (02/04/08) Insufficient Virus Suppression during HAART Is a Strong Predictor for the Development of AIDS-related Lymphoma: German CLINSURV Cohort - (02/25/08) Immunodeficiency and Risk of AIDS-defining and Non-AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006 - (02/25/08) Incidence Anal Squamous Intraepithelial Lesions (SIL) and Predictors of in the SUN Study after One Year of Follow-up - (02/22/08) Renal Report by Wyatt/Klotman Mt Sinai (02/12/08) Kidney - Proteinuria, Glomerular Filtration Rate Reductions, and Associated Factors among HIV-Infected and Uninfected Men in the Multicenter AIDS Cohort Study (MACS) (02/14/08) HIV-Specific Risk Factors for Nonalcoholic Fatty Liver Still Elusive - Written by Mark Mascolini (03/04/08) Racial Disparity in Kidney Disease At Hopkins: Sharp Racial Disparities in Kidney Trouble and End-Stage Disease in HIV+ Cohort - Written by Mark Mascolini - (02/20/08) New ART Drugs in Development PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (03/03/08) Co-Receptor Tropism, ENV Genotype, and in vitro Susceptibility to CCR5 Antagonists During Monotherapy Study with INCB9471 - (02/20/08) Two Schering CCR5 Antagonists Get Spotlight at HIV Conference - Written by Mark Mascolini (02/04/08) A phase I study to explore the activity and safety of SCH 532706, a small molecule chemokine receptor-5 (CCR5) antagonist in HIV-1 infected subjects (02/08/08) VICRIVIROC DEMONSTRATES POTENT AND SUSTAINED VIRAL SUPPRESSION THROUGH 48 WEEKS OF THERAPY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS (02/07/08) Vicriviroc in Combination Therapy With an Optimized Antiretroviral Regimen for Treatment-Experienced Subjects: The VICTOR-E1 Trial (02/07/08) The Effect of Vicriviroc Upon Viral Load in HIV/HCV Co-infected Patients Receiving a Ritonavir-containing Protease Inhibitor Regimen (02/07/08) Two New CCR5 Inhibitors, Actually 3 (02/04/08) GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Peripheral Glucose Disposal in a Healthy Rodent Model System - (02/27/08) Inefficient Renal Transport of Nucleotide Reverse Transcriptase Inhibitor GS-9148 Indicates Its Low Potential for Nephrotoxicity - (02/27/08) New NRTI Apricitabine Versus 3TC in 3TC-Experienced Patients: 24-Week Results - Written by Mark Mascolini - (02/26/08) Pharmacokinetics and Potent Anti-HIV-1 Activity of Amdoxovir Plus Zidovudine in a Randomized Double-blind Placebo-controlled Study - (02/26/08) New Nucleoside, Amdoxovir (DAPD), Potent When Combined With AZT - Written By Mark Mascolini - (02/26/08) Dose Escalation, Safety, Tolerability and Pharmacokinetics of a Novel HIV-1 NNRTI, IDX899 in Healthy Subjects - (02/25/08) Genotypic Resistance and Phenotypic Cross-Resistance Profile in vitro for a Novel NNRTI: IDX899 - (02/25/08) Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings - (02/19/08) ART Clinical Studies Even at Counts Over 350, More CD4s Lower Death Risk in Untreated HIV+ People - Written by Mark Mascolini (02/12/08) Faster Death May Be the Price Paid for Delayed Switching After Failure - Written by Mark Mascolini (02/12/08) "Elite Controller" Study Suggests No "Harmless" Level of HIV, Lose CD4s Faster - Written by Mark Mascolini (02/06/08) Abacavir & MI (myocardial infarction) Risk in D.A.D Study - Written by Mark Mascolini (02/05/08) Steady State Pharmacokinetics and Safety of Atazanavir (ATV) After Treatment with ATV 300 mg/Ritonavir 100 mg (ATV/r) QD + ZDV/3TC During the 3rd Trimester of Pregnancy in HIV+ Women - (02/20/08) Multicenter, Retrospective Study of Incidence and Predictors of Adverse Events Associated With Nevirapine Use in a Cohort of Pregnant and Nonpregnant Women Treated at 3 Urban HIV Clinics in the United States - (02/20/08) Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/06/08) "No Treatment Options" No Longer a Growing Problem in Switzerland - Written by Mark Mascolini (02/06/08) Firstline Nukes Evaluated: What Makes a First Regimen Work? Answers From 79 Trials and Cohorts - Written by Mark Mascolini (02/06/08) Efficacy and Safety of Double-Boosted Saquinavir (SQV)/Lopinavir/Ritonavir (LPV/r) in Nucleoside Pretreated Children at 96 Weeks - (02/26/08) Therapeutic Drug Monitoring of Lopinavir and Saquinavir in Thai HIV-infected Children - (02/25/08) Still Hard to Prove Therapeutic Benefit With Therapeutic Drug Monitoring - Written by Mark Mascolini (02/12/08) Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/14/08) Immediate Antiretrovirals During Acute OI Lower Death Risk: ACTG A5164 - Written by Mark Mascolini (02/12/08) Abacavir (But Not Efavirenz) Weaker in Cohort Study Than in Clinical Trial - Written by Mark Mascolini (02/12/08) Resistance After First Failure Looms as Larger Problem in Poor vs Rich Countries - Written by Mark Mascolini (02/12/08) Longer ART Drug Regimen Found to Help Babies Avoid HIV From Breastfeeding in Africa (02/05/08) Metabolics, Bone Disease Metabolic Complications: A CROI 2008 Summary - Written by David Alain Wohl, MD - The University of North Carolina - (04/03/08) Bone Disease Is Increased in HIV; Cancer Risk Increases with Age & Immune Deficiency - (03/25/08) Review of Bone Posters at CROI 2008 - Written by Turner Overton, M.D. - (03/10/08) HIV and Aging at CROI 2008 - (03/10/08) Influence of NRTI Choice and Efavirenz Versus Lopinavir Treatment Options on Lipoatrophy-Associated Adipose Tissue Toxicity: A Longitudinal Study - (03/07/08) Endothelial Activation Markers Are Linked to HIV Status and Are Independent of ART and Lipoatrophy - (03/05/08) Even Totally Controlled HIV Linked to Atherosclerosis Risk - Written by Mark Mascolini (02/06/08) Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy - (02/27/08) Risk Factors for Reduced Bone Mineral Density In HIV-Infected Individuals In The Modern HAART Era - (02/22/08) Bone Metabolism in HIV: CROI 2008 Update - written by Todd T. Brown, MD, PhD - (02/21/08) HIV & ART Led to Bone Loss (02/19/08) Worse HIV Control--Not Antiretrovirals--Linked to Low Bone Density in Vancouver; ART risk factor in 2nd study - Written by Mark Mascolini (02/19/08) Effects of Diet and Exercise and/or Rosiglitazone on Body Composition and Lipids including Oxidized LDL in HIV+ and HIV- Men and Women - (02/26/08) Metabolic Syndrome Does Not Up Death Risk in HIV Cohort--But Bad Lipids Do - Written by Mark Mascolini (02/14/08) Clinical Associations of Extremity Fat Loss from ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Antiretroviral Therapy (ART) of Naive, HIV-1 infected Subjects (02/14/08) Switching from Combivir [CBV] (AZT/3TC) to Truvada [TVD] (TDF/FTC) Preserves Limb Fat: Results of a DEXA Sub-Study of a 48 Week Randomised Study - (02/19/08) Sustained Treatment With Tesamorelin Needed to Keep Belly Fat Off - written by Mark Mascolini - (02/26/08) Limb Fat Loss Must Reach 30% Before Patients and Physicians See It - Written By Mark Mascolini - (02/26/08) Data on 52-Week Safety and Efficacy of Tesamorelin, a Growth Hormone-releasing Factor Analogue, in HIV-infected Patients with Abdominal Fat Accumulation - (02/22/08) Pharmacology Clinical Pharmacology at CROI 2008: Drug Delivery and Disposition, Drug Interactions, Pharmacogenetics and Applications to Patient Care - written by Courtney V. Fletcher, Pharm.D.(02/20/08) HCV Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08) Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08) The Effect of Hepatitis C Infection on Metabolic Parameters following Initial Therapy of HIV Infected Subjects with Nucleoside +/- NNRTI Regimens - (03/07/08) SLAM-C Study: Maintenance Therapy in Coinfected (02/12/08) Sustained Virological Response to Interferon plus Ribavirin Reduces Liver-related Complications and Mortality in HIV/HCV-co-infected Patients by 9-Fold (02/14/08) Liver Fibrosis in an Outbreak of Acute HCV in HIV-infected MSM; accelerated HCV progression if HIV is contracted before HCV (02/14/08) Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08) On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08) Tenofovir Bolsters Response to IFN/RBV in People With HCV/HIV - Written by Mark Mascolini (02/07/08) Fatty Liver EVOLUTION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN HIV-INFECTED PATIENTS: INCIDENCE, CHARACTERISTICS AND PREDICTORS - (02/27/08) PReP , Prevention PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (03/07/08) Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir - (02/27/08) Circumcision Cuts HSV-2 Risk in Ugandan Men and STDs in Their Wives - Written by Mark Mascolini (02/04/08) Male Circumcision Challenges in African Study (02/04/08) Microbicide Protein Identified (02/04/08) Circumcising Men Slows Herpes Spread by 25%, May Reduce HIV Risk (02/04/08) Hepatitis B Coinfection Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)